CMPS and ATAI remain within ±10% of today's close absent a dated Phase 3 psilocybin readout announcement.

Shares of COMPASS Pathways (ticker: CMPS) and ATAI Life Sciences (ticker: ATAI), two prominent publicly traded psychedelic drug companies, are predicted to move less than 10% in either direction from where they sit today. The reason: any big news that could move the stock — like results from a large Phase 3 (final stage) clinical trial of their lead psilocybin drug COMP360, or a merger deal — is not scheduled to happen imminently. The market has already priced in the current story.

Today's <0.5% moves show narrative is fully priced. Only a scheduled COMP360 readout or M&A term sheet moves these names — neither is on today's calendar.